Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
Authors:
Open Access
- 31 July 2021
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 96 (11) , E408-E410
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsBlood, 2020
- Cell‐mediated and humoral adaptive immune responses to SARS‐CoV‐2 are lower in asymptomatic than symptomatic COVID‐19 patientsEuropean Journal of Immunology, 2020
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyThe Lancet Haematology, 2020
- Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependentJournal of Clinical Investigation, 2020
- Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational studyLeukemia, 2020
- The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammationLeukemia, 2020
- A life‐threatening ruxolitinib discontinuation syndromeAmerican Journal of Hematology, 2017
- Immunological Consequences of JAK Inhibition: Friend or Foe?Current Hematologic Malignancy Reports, 2015
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyLeukemia, 2015
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With MyelofibrosisMayo Clinic Proceedings, 2011